Monday, June 17, 2013

Join the College of American Pathologists THIS WEDNESDAY, JUNE 19, for a one-hour audio conference on the Supreme Court decision from 3-4

Genomic medicine has the potential to be a cornerstone of medical testing, treatment, and clinical integration. Without doubt, the Supreme Court’s unanimous decision invalidating Myriad’s patents on BRCA1 and BRCA2 is already changing the testing landscape for those genes. What other changes can we expect? How will the decision impact pathology and our patients? What did it take to win the case?
As a co-plaintiff in this landmark case, the College of American Pathologists (CAP) and all pathologists have cause to celebrate the Court's ruling. The CAP has assembled a panel of leading experts, including the researcher who discovered BRCA1 and BRCA2, and the ACLU attorney who argued for the plaintiffs and won. Listen as they, along with two leading molecular genetic pathologists, discuss the Supreme Court decision and the impact it will have on patient care.